The Chinese State Food and Drug Administration (SFDA) has granted approval to register Avita Medical's (ASX: AVH) ReCell cell harvesting device on the Chinese market.

The product will be marketed by Helicon Group (ASX: HCG), a WA-headquartered pharmaceutical marketing company specialising in introducing registered medical products into niche markets in China.

The SFDA has approved the product concept and the ReCell kit, but Helicon said there were some importation issues to be overcome before it is on the market.

Helicon has also recently acquired the exclusive licensing rights from EUSA Pharma for Collatamp, an implantable collagen device for the delivery of antibiotics to surgical sites, and is preparing a submission to the SFDA for registration.

Avita Medical was formerly known as Clinical Cell Culture.